Reid W. Merryman

2.1k total citations
44 papers, 433 citations indexed

About

Reid W. Merryman is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Reid W. Merryman has authored 44 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 29 papers in Pathology and Forensic Medicine and 12 papers in Genetics. Recurrent topics in Reid W. Merryman's work include Lymphoma Diagnosis and Treatment (29 papers), CAR-T cell therapy research (21 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Reid W. Merryman is often cited by papers focused on Lymphoma Diagnosis and Treatment (29 papers), CAR-T cell therapy research (21 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Reid W. Merryman collaborates with scholars based in United States, Spain and Italy. Reid W. Merryman's co-authors include Philippe Armand, Scott J. Rodig, Kyle Wright, Aartik Sarma, Roshan V. Sethi, Roch Houot, Charles Herbaux, Steven M. Devine, Franck Morschhauser and Bradley M. Haverkos and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Reid W. Merryman

40 papers receiving 428 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Reid W. Merryman United States 10 272 241 110 62 47 44 433
Nadia Khan United States 11 151 0.6× 202 0.8× 100 0.9× 115 1.9× 53 1.1× 37 431
Mariana Bastos‐Oreiro Spain 11 180 0.7× 126 0.5× 73 0.7× 68 1.1× 136 2.9× 51 363
Praveen Ramakrishnan Geethakumari United States 9 183 0.7× 79 0.3× 49 0.4× 34 0.5× 41 0.9× 51 304
Giorgia Annechini Italy 10 132 0.5× 147 0.6× 45 0.4× 73 1.2× 30 0.6× 25 287
David A. Bond United States 12 199 0.7× 252 1.0× 98 0.9× 247 4.0× 66 1.4× 50 501
Pär Josefsson Denmark 10 124 0.5× 252 1.0× 109 1.0× 179 2.9× 16 0.3× 18 369
Dima El‐Sharkawi United Kingdom 13 140 0.5× 216 0.9× 53 0.5× 158 2.5× 122 2.6× 64 467
Fred Rosenfelt United States 8 188 0.7× 341 1.4× 100 0.9× 195 3.1× 24 0.5× 15 514
Fiona Miall United Kingdom 13 435 1.6× 575 2.4× 171 1.6× 304 4.9× 48 1.0× 32 758
Tiffany Tang Singapore 13 342 1.3× 413 1.7× 186 1.7× 97 1.6× 10 0.2× 34 586

Countries citing papers authored by Reid W. Merryman

Since Specialization
Citations

This map shows the geographic impact of Reid W. Merryman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reid W. Merryman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reid W. Merryman more than expected).

Fields of papers citing papers by Reid W. Merryman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reid W. Merryman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reid W. Merryman. The network helps show where Reid W. Merryman may publish in the future.

Co-authorship network of co-authors of Reid W. Merryman

This figure shows the co-authorship network connecting the top 25 collaborators of Reid W. Merryman. A scholar is included among the top collaborators of Reid W. Merryman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reid W. Merryman. Reid W. Merryman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Johnson, P. Connor, Jeremy S. Abramson, Ann S. LaCasce, et al.. (2025). Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy. Journal of the National Comprehensive Cancer Network. 23(3). 1 indexed citations
3.
Merryman, Reid W., Özgür Mehtap, & Ann S. LaCasce. (2024). Advancements in the Management of Follicular Lymphoma: A Comprehensive Review. Turkish Journal of Hematology. 41(2). 69–82. 2 indexed citations
4.
Wang, Yucai, Melissa C. Larson, Anita Kumar, et al.. (2024). Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 7006–7006. 1 indexed citations
5.
Villasboas, José C., Stephen D. Smith, Carlos Grande, et al.. (2024). Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).. Journal of Clinical Oncology. 42(16_suppl). 7058–7058. 1 indexed citations
6.
Glimelius, Ingrid, Won Seog Kim, Ewa Paszkiewicz‐Kozik, et al.. (2024). Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study. Blood. 144(Supplement 1). 4405–4405. 1 indexed citations
7.
Merryman, Reid W., Justin Rhoades, Kan Xiong, et al.. (2024). Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma. HemaSphere. 8(4). e47–e47. 1 indexed citations
8.
9.
Ryan, Christine E., Rebecca L. Zon, Robert Redd, et al.. (2023). Clinical efficacy and safety of chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with secondary central nervous system involvement. British Journal of Haematology. 203(5). 774–780. 8 indexed citations
10.
Stuver, Robert, Esther Drill, Nivetha Ganesan, et al.. (2023). Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies. Blood. 142(Supplement 1). 3069–3069. 1 indexed citations
11.
Belada, David, Lorenzo Falchi, Sirpa Leppä, et al.. (2023). EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS. Hematological Oncology. 41(S2). 125–127. 4 indexed citations
12.
Merrill, Mwanasha H., Parastoo B. Dahi, Robert Redd, et al.. (2023). A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma. Blood. 142(7). 621–628. 6 indexed citations
13.
Merryman, Reid W., Evandro D. Bezerra, Timothy Voorhees, et al.. (2023). Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma. Blood. 142(Supplement 1). 3511–3511. 1 indexed citations
14.
Akin, Esma A., et al.. (2022). Interim FDG-PET/CT for Response Assessment of Lymphoma. Seminars in Nuclear Medicine. 53(3). 371–388. 9 indexed citations
15.
Shadman, Mazyar, Marcelo C. Pasquini, Kwang Woo Ahn, et al.. (2021). Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 139(9). 1330–1339. 62 indexed citations
16.
Merryman, Reid W., Roch Houot, Philippe Armand, & Caron A. Jacobson. (2020). Immune and Cell Therapy in Non-Hodgkin Lymphoma. The Cancer Journal. 26(3). 269–277. 5 indexed citations
17.
Merryman, Reid W. & Philippe Armand. (2017). Hodgkin lymphoma and PD-1 blockade: an unfinished story. 1. 1–1. 3 indexed citations
18.
Merryman, Reid W., Philippe Armand, Kyle Wright, & Scott J. Rodig. (2017). Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Advances. 1(26). 2643–2654. 79 indexed citations
19.
Merryman, Reid W. & Philippe Armand. (2017). Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. Current Hematologic Malignancy Reports. 12(1). 44–50. 14 indexed citations
20.
Balsara, Rashna D., et al.. (2011). A deficiency of uPAR alters endothelial angiogenic function and cell morphology. PubMed. 3(1). 10–10. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nadia Khan Breakdown of academic impact, for papers by Mariana Bastos‐Oreiro Breakdown of academic impact, for papers by Praveen Ramakrishnan Geethakumari Breakdown of academic impact, for papers by Giorgia Annechini Breakdown of academic impact, for papers by David A. Bond Breakdown of academic impact, for papers by Pär Josefsson Breakdown of academic impact, for papers by Dima El‐Sharkawi Breakdown of academic impact, for papers by Fred Rosenfelt Breakdown of academic impact, for papers by Fiona Miall Breakdown of academic impact, for papers by Tiffany Tang
Rankless by CCL
2026